After ten years, GlaxoSmithKline is closing its neuroscience research and development site in China and is moving it to the company’s hub in the Philadelphia which includes Conshohocken and Collegeville, writes John Carroll for Endpoints News.
“Following a portfolio review and prioritization, GSK has decided to close its Neuroscience R&D Center in Shanghai and move key programs to its global R&D hub in Upper Providence, where they will benefit from co-location with other pipeline R&D programs,” said the company.
[uam_ad id=”54865″]
This represents a further reshuffle of GSK’s neuroscience division which used to be one of its key focuses. It is part of an ongoing reorganization of all of GSK’s R&D operations with the company dropping research into rare diseases and evaluating the benefits of around 30 of its other R&D programs.
GSK is also going through a major product revamp under the leadership of new CEO, Emma Walmsley. She is looking at adding both oncology and auto-inflammatory treatments to the company’s range of drugs. At present, most of its products are focused on treatments for HIV/infectious diseases and respiratory conditions.
Read more about GSK’s reshuffle at Endpoints News by clicking here.
[uam_ad id=”54875″]
